(5R)-5-[2-(甲磺酰)乙基]二氢呋喃-2(3H)-酮 | 98383-40-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: (5R)-5-[2-(甲磺酰)乙基]二氢呋喃-2(3H)-酮
• 英文名称: CI 936
• 英文别名: N⁶-(2,2-diphenylethyl)adenosine；CI-936；N6-(2,2-diphenylethyl)-adenosine；N6-(2,2-diphenylethyl)adenosine；N(6)-(2,2-Diphenylethyl)adenosine；(2R,3R,4S,5R)-2-[6-(2,2-diphenylethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 98383-40-5
• 化学式: C₂₄H₂₅N₅O₄
• 分子量: 447.494
• InChiKey: TUGMXIURLRAWSS-UMCMBGNQSA-N

物化性质

• 沸点：
  778.5±70.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (5R)-5-[2-(甲磺酰)乙基]二氢呋喃-2(3H)-酮 生成 [(3aR,4R,6R,6aR)-4-[6-(2,2-diphenylethylamino)purin-9-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol
  参考文献：
  名称：

  BRISTOL, JAMES A.;MOOS, WALTER H.;TRIVEDI, BHARAT

  摘要：

  DOI：
• 作为产物：
  描述：

  反式硝基苯乙烯 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 乙醚 、 乙醇 、 甲苯 为溶剂， 生成 (5R)-5-[2-(甲磺酰)乙基]二氢呋喃-2(3H)-酮
  参考文献：
  名称：

  N6- [2-（3，5-二甲氧基苯基）-2-（2-甲基苯基）乙基]腺苷及其脲酰胺衍生物。对腺苷A2受体具有高亲和力和高选择性的新型腺苷激动剂。

  摘要：

  DOI：

  10.1021/jm00402a004

文献信息

• N.sup.6 -substituted adenosines for treating pain
  申请人：Warner-Lambert Company

  公开号：US04657897A1

  公开（公告）日：1987-04-14

  N.sup.6 -Substituted diarylalkyladenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are described.

  N.sup.6-取代的二芳基烷基腺苷及其具有极具吸引力的中枢神经系统和心血管特性的药用可接受的酸盐，描述了其制造过程和药用组合物以及使用所述化合物和组合物的方法。
• N.sup.6 -substituted adenosines and method of use
  申请人：Warner-Lambert Company

  公开号：US04657898A1

  公开（公告）日：1987-04-14

  N.sup.6 -Substituted diarylalkyladenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are described.

  本文描述了N.sup.6-取代二芳基烷基腺苷及其药学上可接受的酸盐，具有高度理想的中枢神经系统和心血管特性，以及制造这些化合物的过程和制药组合物，以及使用这些化合物和组合物的方法。
• N6-substituted deoxyribose analogs of adenosines
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0181129A2

  公开（公告）日：1986-05-14

  There is disclosed a compound of the following general formula (I) or a pharmaceutically acceptable acid addition salt thereof, wherein R is cycloalkyl having from three to eleven ring members or R is one of the following groups of the formulae in which n is one, two, or three; X and Y are each, independently, H, lower alkyl, hydroxy, lower alkoxy, benzyloxy, nitro, amino or halogen; and Q is of the fomrula: in which Z is CH3, CH2Hal in which Hal stands for a halogen atom or CH2SCH3; and R2' or R3' are each, independently, H, lower alkyl, lower alkanoyl, benzoyl, benzoyl substituted by lower alkyl, lower alkoxy, or halogen or when taken together are lower alkylidene where the hydroxy groups are free or lower alkanoyl or benzoyl esters thereof. Also disclosed are processes for their manufacture, pharmaceutical compositions and methods for using said compounds and compositions. The compounds have highly desirable central nervous system and antihypertensive properties.

  本发明公开了一种通式如下的化合物（I） 或其药学上可接受的酸加成盐，其中 R 是具有三至十一个环成员的环烷基，或 R 是下式中的一个基团 其中 n 为 1、2 或 3；X 和 Y 各自独立地为 H、低级烷基、羟基、低级烷氧基、苄氧基、硝基、氨基或卤素；Q 为下式的基团： 其中 Z是CH3、CH2Hal（其中Hal代表卤素原子）或CH2S ；R2'或R3'各自独立地是H、低级烷基、低级烷酰基、苯甲酰基、被低级烷基、低级烷氧基或卤素取代的苯甲酰基，或者当它们组合在一起时是羟基游离的低级亚烷基或低级烷酰基或苯甲酰基酯。 此外，还公开了其制造工艺、药物组合物以及使用上述化合物和组合物的方法。 这些化合物具有非常理想的中枢神经系统和抗高血压特性。
• N6- substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0251339A2

  公开（公告）日：1988-01-07

  N⁶-Substituted diarylalkyladenosines of the formula: are disclosed. Processes for their manufacture and pharmaceutical compositions containing the same are also disclosed. The compounds have highly desirable central-nervous system and cardio-vascular properties.

  本发明公开了式：的 N⁶-取代二芳基烷基腺苷，还公开了其生产工艺和含有这些化合物的药物组合物。 这些化合物具有非常理想的中枢神经系统和心血管特性。
• Dog coronary artery adenosine receptor. Structure of the N6-aryl subregion
  作者：Shozo Kusachi、Robert D. Thompson、Noboyuki Yamada、Daniel T. Daly、R. A. Olsson

  DOI：10.1021/jm00156a016

  日期：1986.6

  Previous structure-coronary vasoactivity correlations of the N6-alkyladenosine analogues of N6-[(R)-1-phenyl-2-propyl]adenosine, 1, support the hypothesis that the coronary artery A2 adenosine receptor contains an N6 region of specialized structure. The part of this receptor region that binds the 2-propyl moiety of 1 determines stereoselectivity and contributes to coronary vasoactivity. The present study uses 92 adenosine analogues containing an aryl group in the N6 substituent to test the hypothesis that the N6 receptor region contains an aryl subregion that binds the phenyl moiety of 1 and thereby contributes to its coronary vasoactivity. N6-Aralkyladenosines are often more potent than their alkyl congeners. Two methylene residues seem to provide optimum separation of the aryl group from N6. Among adenosines with semirigid N6 substituents, N6-[(1R,2S)-trans-2-phenylcyclohexyl]adenosine was uniquely active, evidence that when 1 occupies the receptor, the axis of the propyl C-1 to phenyl C-1 bond is nearly in the plane described by N6 and propyl C-1 and C-2. The torsion angle around this bond is unknown. Replacing the phenyl group of N6-2-phenethyladenosine with a thienyl or a 3-pyridyl group raises activity. The structure-activity relationships of the N6-(arylethyl)-, the N6-(arylmethyl)-, and the N6-phenyladenosines differ strinkingly from each other. Taken together, such results support the idea that the N6 region of the dog coronary artery A2 adenosine receptor includes an aryl subregion.